Current progress in immunotherapy of hepatocellular carcinoma

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 482-484

  Sprinzl, Martin F ^a   Galle, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Checkpoint inhibitors; Immunotherapy; Liver cancer; Therapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB;

ABLATION THERAPY; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RESPONSE; EDITORIAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; IMMUNOTHERAPY; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS;

EID: 85009198475     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.009     Document Type: Editorial

References (19)

1. [1] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. [2] Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., et al. Pembrolizumab vs. docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
3. [3] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab vs. docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
4. [4] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab vs. docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
5. [5] Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. Atezolizumab vs. docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
6. [6] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
7. [7] Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
8. [8] Mizukoshi, E., Nakamoto, Y., Arai, K., Yamashita, T., Sakai, A., Sakai, Y., et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53 (2011), 1206–1216.
9. [9] Hiroishi, K., Eguchi, J., Baba, T., Shimazaki, T., Ishii, S., Hiraide, A., et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45 (2010), 451–458.
10. [10] Ali, M.Y., Grimm, C.F., Ritter, M., Mohr, L., Allgaier, H.P., Weth, R., et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 43 (2005), 817–822.
11. [11] Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211 (2014), 781–790.
12. [12] Erinjeri, J.P., Thomas, C.T., Samoilia, A., Fleisher, M., Gonen, M., Sofocleous, C.T., et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol 24 (2013), 1105–1112.
13. [13] Burga, R.A., Thorn, M., Point, G.R., Guha, P., Nguyen, C.T., Licata, L.A., et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64 (2015), 817–829.
14. [14] Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192 (2000), 303–310.
15. [15] Chu, K.F., Dupuy, D.E., Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14 (2014), 199–208.
16. [16] Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology 64 (2016), 2038–2046.
17. [17] Shi, F., Shi, M., Zeng, Z., Qi, R.Z., Liu, Z.W., Zhang, J.Y., et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
18. [18] Ormandy, L.A., Hillemann, T., Wedemeyer, H., Manns, M.P., Greten, T.F., Korangy, F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65 (2005), 2457–2464.
19. [19] Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66 (2017), 545–551.